Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515

Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510

Secretary of the Senate Received: Feb 14, 2007

# LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

1. Registrant Name:
WATSON PHARMACEUTICALS (NJ)
2. Address: 1420 NEW YORK AVENUE NW SUITE 700, WASHINGTON, DC 20005
3. Principal place of business (if different from line 2): City: Corona State/Zip(or Country): CA 92880
4. Contact Name: G. THOMAS LONG Telephone: 2023931220 E-mail (optional): tom.long@watsonpharm.com
Senate ID #: 63837-12 House ID #:
7. Client Name: 🗵 Self
TYPE OF REPORT
8. Year 2006 Midyear (January 1 - June 30): OR Year End (July 1 - December 31): 🔀
9. Check if this filing amends a previously filed version of this report:
10. Check if this is a Termination Report: => Termination Date: 11. No Lobbying Activity:
INCOME OR EXPENSES
Complete Either Line 12 <b>OR</b> Line 13
12. Lobbying Firms
INCOME relating to lobbying activities for this reporting period was:
Less than \$10,000:
\$10,000 or more: => Income (nearest \$20,000):
Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to registrant by any other entity for lobbying activities on behalf of the client).
13. Organizations
EXPENSES relating to lobbying activities for this reporting period were:
Less than \$10,000:
\$10,000 or more: X => Expenses (nearest \$20,000): 440,000.00
14. Reporting Method. Check box to indicate expense accounting method. See instructions for description of options.
Method A. Reporting amounts using LDA definitions only Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code

## LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed

- 15. General issue area code: BUD (one per page)
- 16. Specific lobbying issues:
- H.R. 5384 Agriculture Appropriations for FY 2007; FDA (OGD). S. 1932 Deficit Reduction Omnibus Reconciliation Act. (Medicaid and Medicare provisions.
- 17. House(s) of Congress and Federal agencies contacted: HOUSE OF REPRESENTATIVES Health & Human Services, Dept of (HHS) SENATE
- 18. Name of each individual who acted as a lobbyist in this issue area:

Name: LONG, G. THOMAS Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. None

## LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed

- 15. General issue area code: CPT (one per page)
- 16. Specific lobbying issues:
- H.R. 2795 Patent Reform Act of 2005. Various biodefense and vaccine and drug development bills including S.3, S. 975, S. 2564, S. 1873, and S. 3678.
- 17. House(s) of Congress and Federal agencies contacted: HOUSE OF REPRESENTATIVES SENATE
- 18. Name of each individual who acted as a lobbyist in this issue area:

Name: LONG, G. THOMAS Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. None

## LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed

- 15. General issue area code: HCR (one per page)
- 16. Specific lobbying issues:

H.R. 2345 Counterfeit Drug Enforcement Act of 2005 H.R. 4829 Reducing Fruadulant and Imitation Drug Act of 2005; S. 2300 Lower PRICED Drug Act. Meetings with Members of Congress regarding generic biologics and Food and Drug Administration regulatory activity of interest to the Registrant. Various bills regarding the importation of prescription drugs including; H.R. 328, S. 109, H.R. 700, S. 334, H.R. 753, and S. 184, H.R. 5993, S. 3695; legislation to prohibit the marketing of authorized generic drugs.

17. House(s) of Congress and Federal agencies contacted: HOUSE OF REPRESENTATIVES SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: LONG, G. THOMAS Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. None

## LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed

- 15. General issue area code: MMM (one per page)
- 16. Specific lobbying issues:

This activity includes implementing Medicare Part B changes under the MMA, Medicaid changes under the DRA, and the Part D drug benefit. Contacts with Federal officials re: CMS Part B and Part D regulatory activity. H.R. 1298 and S. 635 Kidney Care Quality and Improvement Act of 2005. Contacts with Members of Congress regarding Centers for Medicare and Medicaid Services (CMS) regulatory activity.

17. House(s) of Congress and Federal agencies contacted: HOUSE OF REPRESENTATIVES Health & Human Services, Dept of (HHS) SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: LONG, G. THOMAS Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. None

Signature: ON FILE Date: Feb 14, 2007

Printed Name and Title: G. THOMAS LONG - VICE PRESIDENT, GOVERNMENT AFFAIR -